Jounce Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Jounce Therapeutics Inc (JNCE) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Jounce Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 148M vs 31M combined for tracked competitors (82.6% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+121.8% annualized vs trailing 12 months).
- Peer revenue share: Jounce Therapeutics Inc accounted for 100.0% of combined revenue among its tracked peer group.
- Peer differentiation: Revenue per employee of $1.18M compares with $0.55M for the peer group (2.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
JNCE Sales vs. its Competitors, Q4 2022
Jounce Therapeutics Inc generated 100.00 % of the combined sales of its peer group.
Jounce Therapeutics Inc vs. its Competitors, Q4 2022
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Jounce Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Jounce Therapeutics inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Jounce Therapeutics Inc's competitor groups requires a Commercial License.
Jounce Therapeutics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Jounce Therapeutics inc | - | - | - | Yes |
| Competitors combined (1) | - | - | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
JNCE Stock Performance relative to its Competitors
JNCE Stock Performance relative to High-Confidence Competitors
Publicly Traded Peers of Jounce Therapeutics inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Jounce Therapeutics inc | 97.15 | 147.87 |
| Surface Oncology Inc | 64.97 | 31.06 |
| SUBTOTAL | 162.12 | 178.93 |
Sources: Jounce Therapeutics inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Jounce Therapeutics inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Jounce Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Portage Biotech Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Jounce Therapeutics Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Jounce Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Jounce Therapeutics inc | 97 | 1,182,976 | -1,080 |
| Surface Oncology Inc | 65 | 554,661 | -1,651,875 |
| PEERS TOTAL | 65 | 554,661 | -1,651,875 |
Jounce Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (93 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.7x | - |
| EV / EBITDA | 4.9x | 21.3x | -16.5x |
| P/B | 0.9x | 5.1x | -4.2x |
| Return on Equity | -0.01 % | industry aggregate | -14.93 % |
| Return on Invested Capital | -37.07 % | -6.17 % (avg) | -30.90 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Jounce Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2019 | 2020 | 2021 |
|---|---|---|---|
| Revenue Growth | 126.79 % | - | - |
| Operating Margin | 35.72 % | - | - |
| Return on Invested Capital | 17.58 % | -49.40 % | -17.25 % |
| P/E | 4.0x | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Jounce Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+121.8% annualized vs trailing 12 months).
Weaknesses
- Return on equity 14.9 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- Industry revenue growing at a healthy 10.0% median pace.
- A meaningful share of tracked competitors (100.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Jounce Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Jounce Therapeutics inc | 4.29 | 7.73 | - |
| Surface Oncology Inc | 2.43 | 6.79 | 0.23 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Jounce Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Jounce Therapeutics inc | Q4 2022 | - | - |
| Surface Oncology Inc | Q2 2023 | - | - |
| PEERS TOTAL | - | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Jounce Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Jounce Therapeutics inc | Q4 2022 | - | +77.0 % |
| Surface Oncology Inc | Q2 2023 | - | - |
Jounce Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Jounce Therapeutics inc | - | - | - |
| Surface Oncology Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Jounce Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Jounce Therapeutics inc | - | 0.66 |
| Surface Oncology Inc | - | 2.09 |
| PEERS AVERAGE | - | 0.91 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.